Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment.

Authors:

G. Natarajan; S. Shankaran; T.L. Nolen; A. Sridhar; K.A. Kennedy; S.R. Hintz; D.L. Phelps; S.B. DeMauro; W.A. Carlo; M.G. Gantz; A. Das; R.G. Greenberg; N.E. Younge; J.M. Bliss; R. Seabrook; P.J. Sánchez; M.H. Wyckoff; E.F. Bell; B.R. Vohr; R.D. Higgins

Abstract:

OBJECTIVE: Among extremely preterm infants, we evaluated whether bevacizumab therapy compared with surgery for retinopathy of prematurity (ROP) is associated with adverse outcomes in early childhood.

METHODS: This study was a retrospective analysis of prospectively collected data on preterm (22-26 + 6/7 weeks' gestational age) infants admitted to the National Institute of Child Health and Human Development Neonatal Research Network centers who received bevacizumab or surgery exclusively for ROP. The primary outcome was death or severe neurodevelopmental impairment (NDI) at 18 to 26 months' corrected age (Bayley Scales of Infant and Toddler Development, Third Edition cognitive or motor composite score

Citation:

Natarajan G, Shankaran S, Nolen TL, et al. "Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment." Pediatrics. 2019;144(2).PubMed

Publication type:

Journal Article

Year:

2019

CPQCC publication:

Yes

PubMed ID:

31337693

PMCID:

PMC6855825